A systems biology approach identifies candidate drugs to reduce mortality in severely ill patients with COVID-19.

ABSTRACT: Despite the availability of highly efficacious vaccines, coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lacks effective drug treatment, which results in a high rate of mortality. To address this therapeutic shortcoming, we applied a systems biology approach to the study of patients hospitalized with severe COVID. We show that, at the time of hospital admission, patients who were equivalent on the clinical ordinal scale displayed significant differential monocyte epigenetic and transcriptomic attributes between those who would survive and those who would succumb to COVID-19. We identified messenger RNA metabolism, RNA splicing, and interferon signaling pathways as key host responses overactivated by patients who would not survive.

SUBMITTER: Fava VM 

PROVIDER: S-EPMC9159580 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature